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Abstract
Background: Interferon-gamma (IFN-γ) ELISPOT assays incorporating Mycobacterium tuberculosis-
specific antigens are useful in the diagnosis of tuberculosis (TB) or latent infection. However, their
utility in patients with advanced HIV is unknown. We studied determinants of ELISPOT responses
among patients with advanced HIV infection (but without active TB) living in a South African
community with very high TB notification rates.
Methods: IFN-γ responses to ESAT-6 and CFP-10 in overnight ELISPOT assays and in 7-day whole
blood assays (WBA) were compared in HIV-infected patients (HIV+, n = 40) and healthy HIV-
negative controls (HIV-, n = 30) without active TB. Tuberculin skin tests (TSTs) were also done.
Results: ELISPOTs, WBAs and TSTs were each positive in >70% of HIV- controls, reflecting very
high community exposure to M. tuberculosis. Among HIV+ patients, quantitative WBA responses
and TSTs (but not the proportion of positive ELISPOT responses) were significantly impaired in
those with CD4 cell counts <100 cells/µl compared to those with higher counts. In contrast,
ELISPOT responses (but not WBA or TST) were strongly related to history of TB treatment; a
much lower proportion of HIV+ patients who had recently completed treatment for TB (n = 19)
had positive responses compared to those who had not been treated (11% versus 62%,
respectively; P < 0.001). Multivariate analysis confirmed that ELISPOT responses had a strong
inverse association with a history of recent TB treatment (adjusted OR = 0.06, 95%CI = 0.10–0.40,
P < 0.01) and that they were independent of CD4 cell count and viral load. Among HIV+ individuals
who had not received TB treatment both the magnitude and proportion of positive ELISPOT
responses (but not TST or WBA) were similar to those of HIV-negative controls.
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Conclusion: The proportion of positive ELISPOT responses in patients with advanced HIV
infection was independent of CD4 cell count but had a strong inverse association with history of
TB treatment. This concurs with the previously documented low TB risk among patients in this
cohort with a history of recent treatment for TB. These data suggest ELISPOT assays may be useful
for patient assessment and as an immuno-epidemiological research tool among patients with
advanced HIV and warrant larger scale prospective evaluation.
Background
The HIV-associated tuberculosis (TB) epidemic in sub-
Saharan Africa is fuelling a global increase in TB incidence
of 1% per year [1]. TB incidence rates in southern Africa
have reached almost unprecedented levels [2] and much
of this disease remains undetected in the community [3].
This escalating epidemic led to the declaration by the
World Health Organisation in 2005 of "a regional emer-
gency requiring urgent and extraordinary actions" [4].
However, most existing tools with which to confront the
TB epidemic are blunt, especially those used for diagnosis
of Mycobacterium tuberculosis infection and disease in HIV-
infected patients.
Recent developments of immune-based assays to detect
Mycobacterium tuberculosis infection are a significant
advance [5]. ESAT-6 and CFP-10 are two proteins encoded
by the RD1 genomic segment of M. tuberculosis, which is
absent from all BCG strains and the vast majority of envi-
ronmental mycobacteria [6-8]. As a result, enzyme-linked
immunospot (ELISPOT) assays that detect interferon-
gamma (IFN-γ) release in response to these antigens dif-
ferentiate between M. tuberculosis infection and immune
sensitisation by BCG vaccination or exposure to environ-
mental mycobacteria. In outbreaks of TB in the UK, ELIS-
POT responses among contacts showed better correlation
with the degree of exposure than tuberculin skin tests
(TSTs) [9,10]. Among HIV-negative patients with culture-
positive TB, ELISPOT assays have a sensitivity of approxi-
mately 80–90% [11-13]. Moreover, increasing evidence
suggests that ELISPOT responses in human and bovine
models correlate with mycobacterial load during antitu-
berculosis treatment [13-18].
At present, very few studies have examined the utility of
ELISPOT assays in HIV-infected individuals. In a study
from Zambia, ELISPOT responses to ESAT-6 or CFP-10
were positive in 90% (n = 39) of HIV-infected patients
with sputum smear-positive pulmonary TB [19]. Also,
when used in the diagnosis of TB in South African chil-
dren, the sensitivity of the assay was not significantly
impaired by HIV coinfection [12]. More recently the assay
was found to be relatively unimpaired in the detection of
either latent M. tuberculosis infection or active TB in
patients with moderately advanced HIV infection [20,21].
However, responses in those with advanced HIV have not
previously been reported.
The aim of the present study was to identify determinants
of ELISPOT responses among patients with advanced HIV
infection (but not active TB) living in a South African
community with very high TB incidence. Overnight IFN-γ
ELISPOT assay responses were assessed among a group of
HIV-infected patients enrolling in an antiretroviral treat-
ment service and were compared with responses in a
group of healthy controls living in the same community.
To provide greater insight, these responses were compared
to 7-day whole blood assays (WBA) of IFN-γ release and
TSTs.
Methods
HIV-infected (HIV+) patients were recruited to the study
at the antiretroviral treatment clinic based at the Gugu-
lethu Community Health Centre in Cape Town. The study
cohort and clinic have previously been described in detail
[22-25]. The district has a predominantly African popula-
tion of over 300,000, the vast majority of whom live in
conditions of low socioeconomic status. In 2003 the ante-
natal HIV seroprevalence was 28% and the annual TB
notification rate exceeded 1,000/100,000 [26]. Patients
were referred to the ART programme for evaluation for eli-
gibility for antiretroviral treatment under national guide-
lines.
Consecutive HIV+ patients were recruited to the study
before starting antiretroviral treatment. Non-pregnant
adults between the ages of 18 and 50 years, who were not
currently receiving antituberculosis treatment nor had evi-
dence of active TB were eligible. Details of previous med-
ical history were obtained from the referral letter and were
cross-checked with the patient. Patients were clinically
characterised and carefully evaluated for TB. Available
investigations for TB included sputum smear microscopy
and liquid culture (MGIT, Becton Dickinson, Sparks, Mar-
yland, USA), chest radiology, and fine needle aspiration
of lymphadenopathy for cytology and culture. Nebulised
sputum induction was accessible when required. Patients
with active TB diagnosed at baseline were excluded as
were those who subsequently developed TB within 4
months of the recruitment date since they may have had
active sub-clinical TB at the time of testing. Standard
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antituberculosis treatment nationally uses a 6-month
rifampicin-containing regimen and primary and second-
ary isoniazid prophylaxis is not recommended by the
national TB control programme.
Healthy HIV- control patients aged 18–50 years were
recruited from the same community. These individuals
were part of a prospective cohort being studied in prepa-
ration for phase III HIV vaccine trials. Consecutive indi-
viduals with two negative HIV tests three months apart
who remained asymptomatic and had no previous history
of TB or other significant morbidity were enrolled.
At a single clinic visit venous blood was taken and TSTs
were done using 2 TU purified protein derivative (PPD)
RT23 (Statens Serum Institut, Copenhagen, Denmark) on
the volar aspect of the forearm. TSTs were read by a single
health care worker experienced in the technique, measur-
ing the diameter of induration at 48–72 hours using calli-
pers. Plasma HIV-1 load was measured using Versant™
HIV-1 RNA 3.0 branched chain DNA assay (Bayer Health-
Care, Leverkusen, Germany) and blood CD4 cell counts
were measured by flow cytometry using FACSCount™
(Becton Dickinson Inc., Franklin Lakes, NJ, USA). All sub-
jects studied gave written informed consent. The study
was approved by the Research Ethics Committee of the
University of Cape Town and conformed to the declara-
tion of Helsinki.
ELISPOT assays
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from heparinized venous blood by Ficoll-Paque cen-
trifugation. A commercially available IFN-γ ELISPOT kit
containing a pre-coated 96-well plate was used (Mabtech,
Stockhom, Sweden). Paired wells with 250,000 cells/well
were stimulated with anti-CD3 antibody at 100 ng/ml
(positive control, Mabtech), were left unstimulated (neg-
ative control) or contained the following antigens each at
5 µg/ml final concentration: PPD RT49 (Statens Serum
Institut) or recombinant ESAT-6 and CFP-10 (Lionex,
Braunschweig, Germany). After incubation for 18 hours,
plates were developed according to the manufacturer's
protocol. Plates were read on an Immunospot Series 3B
Analyzer (Cellular Technology, Cleveland, OH, USA) and
were retained for visual inspection in the case of anomaly.
Low level spot counts in unstimulated negative control
wells were subtracted from the test well results. The mean
number of spot-forming units (SFU) in paired wells was
multiplied by 4 to provide SFU/106 PBMC. Counts of ≥ 20
SFU/106 PBMC that were at least ≥ 2-fold greater than
background counts were predefined as positive responses.
Using this cut-off, this assay produces very similar results
to other commercially available and 'in-house' assays per-
formed in the same laboratory [20,21].
Whole blood assays
Whole blood assays were done using a methodology sim-
ilar to that described previously [27,28]. Heparinized
whole blood was diluted 5-fold using RPMI 1640 supple-
mented with penicillin, streptomycin and 2 mM L-
glutamine and was plated into 96-well plates in the pres-
ence of antigen or mitogen or left unstimulated. Phyto-
haemagglutinin (PHA, Sigma, St. Louis, MS, USA), PPD
RT49, and recombinant ESAT-6 and CFP-10 were all used
at a final concentration of 5 µg/ml. Any small residual
traces of endotoxin in antigen preparations were neutral-
ised using 10 µg/ml polymyxin B sulphate (Sigma) as ver-
ified in pilot experiments. Day 7 supernatants were
harvested following incubation at 37°C. All assays were
piloted and conditions, antigen concentrations and time-
points were optimised using patient and control samples.
IFN-γ responses to recombinant ESAT-6 were equivalent
when compared with those generated using a sample of
recombinant antigen from Statens Serum Institut, Copen-
hagen.
Concentrations of IFN-γ were determined in paired sam-
ples of supernatant using an ELISA with a standard curve
that ranged from 10,000 pg/ml to 41 pg/ml and using pre-
viously described methodology [28,29]. Background con-
centrations of IFN-γ were subtracted from sample results,
which were then categorised as positive if ≥2-fold higher
that the lower limit of detection of the assay. Negative
control values falling below the lower limit of detection
were assigned half the value of the lowest standard.
All laboratory assays were done blinded to the status of
the patients.
Data analysis
χ2, Fisher's exact and Mann-Whitney U tests were used to
compare proportions and medians as appropriate. Assay
responses were evaluated as continuous (quantitative)
variables and as categorical variables (positive or negative
responses) according to the thresholds stated above. Asso-
ciations between patient characteristics and positive ELIS-
POT and WBAs were examined using univariate analyses
and multiple logistic regression models. CD4 cell count,
plasma viral load and history of previous TB were
included in the multivariate models a priori; age and sex
were included if there was a trend towards an association
(p < 0.10). SAS version 8.2 (SAS, Cary, North Carolina,
USA) and Prism version 4.0 (GraphPad Software, San
Diego, CA, USA) software were used for data analysis.
Results
Patient characteristics
A total of 77 subjects were recruited; 7 were excluded due
to failed ELISPOT assays (n = 4; no positive control
response or technical error) or the development of possi-
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ble TB (n = 3). Eleven individuals invited to participate
declined (predominantly due to transportation difficul-
ties). Among those included in the analysis, 40 were HIV+
patients being evaluated for antiretroviral treatment; these
had baseline characteristics (Table 1) which were similar
to those described in previous reports of this treatment
cohort [22-24]. None of the patients had serious co-mor-
bidity (such as lymphoma, Kaposi's sarcoma requiring
cytotoxic chemotherapy or diabetes mellitus) that might
have affected T cell assays. CD4 cell counts showed that
immunodeficiency was advanced in most patients; 48%
had a history of completed treatment for TB within the
preceding 3 years (Table 1) consistent with previous find-
ings [22]. The median period since completion of TB treat-
ment was 4 months (IQR, 2–13 months). HIV- controls
(n = 30) had similar age and sex distribution as HIV+
patients (Table 1).
A large proportion (58%) of the HIV+ patients had cuta-
neous anergy to PPD (Table 1) and TSTs reactions >10
mm occurred in a significantly lower proportion of HIV+
patients than HIV- controls (43% versus 77%, P < 0.05).
TST responses were significantly associated with CD4 cell
count; the proportion of patients with a TST response >10
mm was much lower among those with CD4 cell counts
<100 cells/µl (n = 17) compared to those with CD4 cell
counts >100 cells/µl (n = 23) (16% versus 56%, respec-
tively; P < 0.05). In contrast, TST responses were not sig-
nificantly associated with history of TB treatment (P =
0.2).
ELISPOT and WBA results
In all 70 subjects included in the analysis the positive con-
trol stimuli produced measurable responses in ELISPOT
assays and WBAs. The magnitude of responses to all stim-
uli were significantly lower among HIV+ patients com-
pared to HIV- controls (Table 2). However, in contrast to
TSTs, the magnitude of these responses in HIV+ patients
was not significantly associated with CD4 cell count using
either assay. Instead IFN-γ responses, especially ELISPOT
results, were strongly associated with history of previous
TB treatment; responses among treated patients were
lower than those who had no history of treatment (Table
2).
We next calculated the proportions of patients with assay
responses categorised as positive according to the prede-
fined thresholds (Figure 1). In general, greater propor-
tions of 7-day WBA responses were positive compared to
the overnight ELISPOT assay. Furthermore, the propor-
tions of positive responses were typically greater using
PPD compared to RD1 antigens.
Positive responses to RD1 antigens were detected in 70%
of healthy HIV- controls using the ELISPOT assay and in a
significantly greater proportion using the 7-day WBAs
(93%; P < 0.05) (Figure 1). Positive responses to PPD
were also observed in very high proportions of HIV- con-
trols using both assays (Figure 1). Similar to the quantita-
tive responses (Table 2), the proportions of positive
ELISPOT responses in HIV+ patients were also very
strongly associated with previous history of TB treatment
(Figure 1). Compared to those who had not previously
received TB treatment, treated patients had a 5.6-fold
lower proportion of positive ELISPOT responses to RD1
antigens (P < 0.01) and a 2.4-fold lower proportion of
positive ELISPOT responses to PPD (P = 0.02) (Figure 1).
In marked contrast, WBA responses in HIV+ patients did
Table 1: Characteristics of HIV-negative controls (HIV-) and HIV-infected patients (HIV+)
Characteristic HIV- controls HIV+ patients
All With history of TB With no history of TB
Number 30 40 19 21
Median age (years) 28 31 30 32
Female 23 (77) 32 (80) 13 (68) 19 (90)
CD4 count (cells/µL)
Median (IQR) - 114 (72–246) 98 (44–160) 117 (77–267)
Distribution
0–99 - 17 (43) 10 (53) 7 (33)
100–199 - 10 (25) 5 (26) 5 (24)
≥200 - 13 (32) 4 (21) 9 (43)
Median viral load 5.0 (4.5–5.3) 5.0 (4.6–5.4) 4.9 (4.4–5.3)
TST (mm)
0 6 (20) 23 (58) 13 (68) 10 (48)
1–9 1 (3) 0 (0) 0 (0) 0 (0)
≥100 23 (77) 17 (43) 6 (32) 11 (52)
Unless otherwise stated, values show numbers (%) of patients.
Viral load in log copies/mL. TST = tuberculin skin test
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not show a significant inverse association with history of
TB treatment (P > 0.25 for each comparison) (Figure 1).
Thus, there was a clear dissociation between ELISPOT
responses and WBA responses in those who had previ-
ously been treated for TB (Figure 1).
We next examined the effect of CD4 cell count on the pro-
portion of positive assay responses by comparing the
results of those with CD4 cell counts <100 cells/µl (n =
17) with those of patients with CD4 cell counts >100
cells/µl (n = 23). There was no significant difference
between these groups using the WBA (82% vs 61%,
respectively; P = 0.18) although there was a non-signifi-
cant trend towards an association using the ELISPOT assay
(24% vs 52%, respectively; P = 0.10). Importantly, how-
ever, history of TB treatment is confounded as a variable
by CD4 cell count in this cohort [22] (Table 1). Thus, we
next analysed ELISPOT responses stratified by both CD4
cell count and history of TB treatment. This clearly
showed that responses were strongly associated with his-
tory of TB treatment but not with CD4 cell count (Figure
2).
To confirm these findings we next did multivariate analy-
sis to identify factors independently associated with posi-
tive ELISPOT responses to RD1 antigens (Table 3). This
showed that ELISPOT responses were not significantly
associated with CD4 cell count or viral load but that there
was a highly significant independent association with his-
tory of TB treatment.
Responses in HIV+ patients with no history of TB 
treatment
Results thus far indicated that HIV+ patients who did not
have a history of recent TB treatment were much more
likely to have positive ELISPOT responses to RD1 antigens
than those who had been treated. We reasoned that while
treated patients were likely to have cleared any viable
mycobacteria, untreated patients would have a similar risk
of latent M. tuberculosis as HIV- controls. We therefore
compared IFN-γ responses in HIV- controls and the sub-
group of HIV+ patients with no history of TB treatment.
There was indeed no significant difference between these
groups in quantitative ELISPOT responses to PPD, ESAT-6
and CFP-10 (P > 0.1 for all comparisons) whereas quanti-
tative WBA responses were much lower in the HIV+ sub-
group (P < 0.01 for all stimuli) (Table 2). Moreover, the
proportion of positive ELISPOT responses did not signifi-
cantly differ between the HIV- and the untreated HIV+
subgroup (P = 0.55) (Figure 2).
Table 2: Quantitative interferon-γ (IFN-γ) responses to anti-CD3 (positive control) and mycobacterial antigens as assessed by 
ELISPOT assay and 7-day whole blood assay (WBA)
Patient 
characterist
ics
ELISPOTa WBAb
Anti-CD3 PPD ESAT-6 CFP-10 PHA PPD ESAT-6 CFP-10
HIV- (n = 
30)
1723 (846–
2471)
61 (26–214) 24 (7–199) 30 (6–89) >10,000 >10,000 4820 3678
HIV+ (n = 
40)
626 (398–
2015)
21 (2–53) 7 (2–46) 6 (0–39) 3991 799 355 96
P value 0.012 0.001 0.004 0.010 <0.001 <0.001 <0.001 <0.001
HIV+ 
CD4>100c 
(n = 23)
654 (290–
2296)
30 (4–64) 16 (2–58) 30 (0–82) 4213 616 34 49
HIV+ 
CD4<100 (n 
= 17)
600 (400–
1912)
8 (2–49) 2 (1–17) 1 (1–10) 2550 1034 528 125
P value 0.93 0.42 0.19 0.12 0.13 0.89 0.14 0.12
HIV+ no 
previous TB 
Rxd (n = 19)
476 (269–
2299)
34 (3–147) 22 (2–80) 36 (1–80) 6938 1529 495 179
HIV+ 
previous TB 
Rx (n = 21)
1020 (400–
1844)
6 (2–42) 5 (0–14) 0 (0–6) 2749 313 65 20
P value 0.70 0.085 0.044 0.028 0.10 0.115 0.220 0.038
aELISPOT responses expressed as median (interquartile range) spot-forming units/106 peripheral blood mononuclear cells.
bWBA responses expressed as median values in pg/mL.
cCD4 cell count in cells/µL.
dTB Rx = treatment for tuberculosis
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Discussion
This study conducted in a setting with very high TB bur-
den is, to our knowledge, the first to assess the utility of
ELISPOT responses to M. tuberculosis-specific antigens
among HIV-infected patients with advanced immunodefi-
ciency. To provide further insight into the determinants of
such responses, we compared the overnight ELISPOT
assay (which assesses rapid effector memory T cell
responses [18,30,31] with a 7-day IFN-γ WBA (which
reflects central memory T cell responses [32]. We found
that both assays were able to detect IFN-γ responses to
ESAT-6 and CFP-10 in a substantial proportion of HIV+
patients despite the low median CD4 cell count of 114
cells/µl. The proportion of positive ELISPOT responses
was independent of CD4 cell count in stratified and mul-
tivariate analyses (Table 2, Figure 2); instead responses
were strongly associated with history of TB treatment (Fig-
ures 1 and 2; Tables 2 and 3). Almost half the HIV+
patients had completed treatment for TB a median of 4
months earlier, resulting in likely clearance of the burden
of viable mycobacterial infection; this was reflected by a
low proportion of positive ELISPOT responses in these
patients but persistence of a high proportion of positive
Proportion of positive ELISPOT IFN-γ responses to M. tuber-cul sis-specific antigens (ESAT-6 and/or CFP-10) among HIV- ontrols ( = 30) compared to HIV+ patients (n = 40) s rati-fied by CD4 ell cou t >100 cells/µl (n = 23) or <10  cells/µl(n = 17) a d accordi g to hist ry of rec nt TB treatment (n = 19) or no hist ry of suc  tr atment (n = 2 )Figure 2
Proportion of positive ELISPOT IFN-γ responses to M. tuber-
culosis-specific antigens (ESAT-6 and/or CFP-10) among HIV- 
controls (n = 30) compared to HIV+ patients (n = 40) strati-
fied by CD4 cell count >100 cells/µl (n = 23) or <100 cells/µl 
(n = 17) and according to history of recent TB treatment (n 
= 19) or no history of such treatment (n = 21). ns = not sig-
nificant
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Table 3: Multivariate analysis of factors associated with positive IFN-γ ELISPOT responses to ESAT-6 or CFP-10 in HIV+ patients (n = 
40)
Variable Crude OR P value Adjusted OR P value
Age <31 years 1.00 - -
>31 years 0.58 (0.16–2.12) 0.41 - -
Sex Male 1.00 - -
Female 5.44 (0.60–49.56) 0.13 - -
CD4 count >100 1.00 1.00
(cells/µL) <100 0.34 (0.08–1.34) 0.12 0.58 (0.11–3.16) 0.53
Log viral load <5.0 1.00
(copies/mL) >5.0 0.39 (0.10–1.49) 0.17 0.30 (0.05–1.69) 0.17
History of TB No 1.00
Yes 0.07 (0.01–0.40) <0.01 0.06 (0.10–0.40) <0.01
OR = odds ratio
Proportion of positive IFN-γ ELISPOT responses and 7-day IFN-γ whole blo d assay (WBA) responses to ESAT-6 and/or CFP-10 (RD1) an purified protein derivative (PPD) amongHIV  controls (n = 30) and HIV+ pati nts (n = 40) subdividedint  th se with (n = 19) or without (n = 21) a history of pre-vious tub rcul si reatment (TB Rx)Figure 1
Proportion of positive IFN-γ ELISPOT responses and 7-day 
IFN-γ whole blood assay (WBA) responses to ESAT-6 and/or 
CFP-10 (RD1) and purified protein derivative (PPD) among 
HIV- controls (n = 30) and HIV+ patients (n = 40) subdivided 
into those with (n = 19) or without (n = 21) a history of pre-
vious tuberculosis treatment (TB Rx). ELISPOT assay 
responses in HIV+ patients were strongly associated with 
history of TB treatment. *In HIV+ patients who had previ-
ously received TB treatment, the proportions of positive 
responses to RD1 and PPD antigens were significantly lower 
using the ELISPOT assay than the WBA (P < 0.05 for each 
comparison). ns = not significant.
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WBA (memory) responses. In contrast, ELISPOT
responses in HIV+ patients with no history of TB treat-
ment did not significantly differ from those of HIV- con-
trols. Collectively, these observations suggest the ELISPOT
assay provides data that are clinically and immuno-epide-
miologically informative in patients with advanced HIV.
Antigen stimulation in 7-day WBA permits T cells to dif-
ferentiate and proliferate, leading to amplification of IFN-
γ responses. Similar to lymphocyte proliferation assays,
WBAs thereby provide an assessment of memory
responses to antigens encountered at any time past or
present. In contrast, the overnight ELISPOT assay detects
rapid effector memory cells; such cells are thought to have
recently encountered antigen from viable organisms in
vivo and can rapidly release IFN-γ when re-exposed to anti-
gen in vitro [18,30,31]. Thus, ELISPOT responses appear to
be more strongly associated with current antigen load
rather than with past antigen exposure [13-18]. These facts
provide a logical rationale for the very strong inverse asso-
ciation between ELISPOT responses (but not 7-day WBA
responses) and history of recent TB treatment in HIV+
patients.
The HIV- control group was recruited in the same commu-
nity and had similar demographic characteristics as the
HIV+ group and so were likely to have similar prior expo-
sure to M. tuberculosis. Retention within an HIV-negative
cohort for ≥3 months provided the opportunity to pro-
spectively verify that these patients were free of both TB
and HIV. Positive WBA responses to mycobacterial anti-
gens were detected among a very high proportion of HIV-
controls, which is consistent with extremely high rates of
previous exposure to M. tuberculosis in this community.
Similar to a study in a neighbouring community in Cape
Town [20], TSTs ≥ 10 mm and ELISPOT responses to RD1
antigens were positive in 70% and 77% of HIV- controls,
respectively, consistent with high rates of latent M. tuber-
culosis infection.
The HIV+ group was drawn from a very well-characterised
cohort of patients enrolling for antiretroviral treatment in
which risk factors for TB have been established [22]. An
important finding previously reported was that patients
who had completed successful TB treatment within the
preceding 2 years had an approximately 5-fold lower risk
of active TB compared to those who had not [22]. The
ELISPOT results in this study strongly concur with this
observation. We suggest that successful TB treatment
would have cleared viable mycobacterial infection, result-
ing in low risk of reactivation TB and negative ELISPOT
responses due to absence of antigen. An alternative
hypothesis to explain the ELISPOT data would be that
those who had previously had TB developed lasting sup-
pression of IFN-γ responses to RD1 antigens, although the
WBA data do not support this.
Our findings are consistent with previous studies showing
that HIV infection does not appear to substantially under-
mine ELISPOT responses in patients with either active TB
[12,19,21] or latent M. tuberculosis infection [19-21]. In
two separate studies, Rangaka et al. found that assay
responses to RD1 antigens were not significantly impaired
in two cohorts of patients with latent infection and mod-
erate HIV-associated immunodeficiency (both median
CD4 cell counts of 392 cells/µl and 464 cells/µl) [20,21].
Our data extend this observation to patients with
advanced immunodeficiency (median CD4 cell count =
114 cells/µl). Although we found no impact of CD4 cell
count on the proportion of positive responses, there was
a trend towards overall quantitative ELISPOT responses
being reduced in those with CD4 cell counts <100 cells/µl
and the study lacks the statistical power to adequately
assess this.
The normalised input of peripheral mononuclear cells
used in ELISPOT assays may, in part, explain why this
assay appears to retain utility among patients with low
CD4 cell counts. This also might explain why studies
using a commercially available data overnight IFN-γ
whole blood assay (QuantiFERON-TB Gold, Cellestis,
Melbourne, Australia) in which the cell input is not nor-
malised have found that responses do not appear to be
greatly affected in HIV-infected patients with moderate
immunodeficiency but that there was a high rate of inde-
terminate results among those with advanced immunode-
ficiency [20,33,34]. It cannot be assumed that only CD4 T
cell responses are measured by these assays as other IFN-
γ-secreting PBMC subsets such as CD8 T cells and NK cells
may also be detected. Future immunophenotypic studies
would be useful in this regard.
A high proportion of HIV+ patients had anergic TSTs, con-
firming the known limited utility of this test in advanced
HIV. Moreover, both TST responses and quantitative WBA
responses to mycobacterial antigens were very strongly
associated with CD4 cell count, contrasting with the ELIS-
POT assay. A potential reason for this is that both TST and
WBA responses depend on interleukin-2-mediated T cell
proliferation, which is markedly inhibited by HIV infec-
tion [35,36]. In contrast, the overnight ELISPOT assay
detects terminally differentiated effector cells [18,30] and
is therefore independent of T cell proliferation.
This study has certain limitations. Case control studies
may be subject to selection bias. However, the characteris-
tics of the HIV+ group were representative of those previ-
ously described in this cohort [22] and HIV- controls had
similar demographic characteristics as HIV+ patients and
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were enrolled within the community rather than at health
facilities. The assays used are research tools and are not
directly comparable with commercially available IFN-γ-
release assays currently used in clinical practice. Although
the group of HIV+ patients with a history of TB treatment
was heterogeneous with regard to the time since comple-
tion of TB treatment, we have previously found that such
patients have a substantially lower risk of TB [22]. Thus,
history of previous TB treatment was included as a key var-
iable within the analyses. This study, however, was not
designed to specifically evaluate the impact of TB treat-
ment on ELISPOT responses and the data should not be
over-interpreted in this regard. Common to all such stud-
ies, the sensitivity of the ELISPOT assay in diagnosis of M.
tuberculosis infection in this population cannot be defini-
tively evaluated in the absence of a gold standard. The
study included few HIV-infected patients with high CD4
cell counts and this may have limited the ability to fully
evaluate the effect of CD4 cell count on ELISPOT
responses. However, our findings are consistent with
other published data [20,21]. The number of patients
studied was limited, but in view of the very high rates of
TB exposure in this community and very strong statistical
associations observed, the aims of the study were never-
theless achieved.
Conclusion
This study provides evidence that the IFN-γ ELISPOT assay
retains utility among patients with advanced HIV infec-
tion as suggested by the following key observations: (i)
the proportion of positive responses was not associated
with CD4 cell count in stratified and multivariate analy-
ses; (ii) responses were strongly related to history of TB
treatment – a known key factor associated with TB risk in
this patient population; (iii) responses in HIV+ patients
who had not been treated for TB in the past were similar
to those of HIV- controls. Collectively these data indicate
that the ELISPOT assay provides data that are informative
in patients with advanced HIV and is therefore likely to be
useful for patient assessment and as an immuno-epidemi-
ological tool. These data provide an important basis for
the justification of future large scale evaluation of the
assay in prospective cohort studies of patients with
advanced HIV.
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